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ABSTRACT 
This study was designed to observe the effects of an antioxidant gel on 
oxidative stress levels and salivary flow rates in xerostomic patients. In this 
prospective, nested, double blind, crossover, randomized clinical trial, 
unstimulated whole saliva was collected from 36 subjects, who were randomly 
divided into two groups: Active-Placebo (n=21) and Placebo-Active (n=15). 
Subjects either received the active or placebo gel for the first 4 weeks of the 
study and then underwent a two-week washout period between weeks 4 and 6. 
Subjects were then given the opposite gel product at week 6 and instructed to 
use this product for 4 more weeks. Salivary samples were collected at week 
0,2,4,6,8,10. Statistical analysis was completed with paired t-test and mixed 
model analysis. Further analysis of the subset of participants with salivary flow 
rates below 0.200 mL/min and below 0.100 mL/min was also completed. 
Results indicate that oxidative stress levels did not change significantly 
over the course of the study in either group. Upon evaluation of participants with 
salivary flow rates below 0.200 mL/min, a statistically significant increase in 
salivary flow rate was noted in subjects in the active-placebo groups (P<.05). 
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NOMENCLATURE 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
 
Saliva and Dry Mouth 
Saliva is important to maintain homeostasis within the oral cavity. Its 
humidifying and lubricating properties allow for speech and swallowing while 
also preventing mechanical insult to the oral tissues. Whole saliva consists of 
the secretions from the major and minor salivary glands along with the gingival 
crevicular fluid.1, 2 Normal unstimulated salivary flow rates are within the range of 
0.3-0.4 mL/min. It is interesting to note that this range includes a large standard 
deviation, thus making it difficult to predict a “normal” value.3 Women are noted 
to have decreased amounts of saliva compared to men. Furthermore, although 
salivary flow rate may diminish in either sex, women may be more likely to 
experience decreased salivary output with an increase in age.4 The actual 
volume of saliva does not necessarily dictate the subjective feeling of xerostomia 
as the sensation of oral dryness has been reported by patients with normal 
salivary flow rates. Studies show that most of these xerostomic patients have a 
history of use of medications associated with dry mouth, systemic conditions 
leading to dry mouth, or a habit of mouth breathing.5-7  
Composition of Saliva 
Saliva is composed of 99% water, but the main difference from water is 
that saliva also contains mucins, which are glycosylated proteins that aid in the 
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lubrication process allowing for mastication, speech, and swallowing.8 The main 
mucins seen in saliva are MUC5B and MUC7. These mucins form the acquired 
enamel pellicle thus creating a gap between any two surfaces in the mouth and 
diminishing trauma from abrasion of intraoral surfaces.9, 10 However, studies 
have shown that replacing MUB5B or MUC7 does not alleviate dry mouth 
concerns; rather the combination of both mucins and other proteins creates the 
acquired pellicle on teeth.11 Therefore, finding salivary replacement products is a 
difficult task. Most products are only able to offer palliative relief.  
Functions of Saliva 
Saliva is important for removal of microorganisms, leukocytes, food debris 
and desquamated epithelial cells by the process of swallowing. Most important 
to clear after meals are fermentable carbohydrates that limit the acidic insult to 
the oral cavity and prevent caries. Unstimulated and stimulated saliva provide 
the liquid to aid in swallowing during meal times. In patients with reduced 
salivary levels, the clearance of food particles is reduced thus making these 
patients more prone to dental caries.12 Furthermore, saliva exhibits antiviral, 
antibacterial, and antifungal properties that allow regulation of the oral flora.13   
Saliva is the hypotonic solution in which food particles can disseminate to 
the various taste buds and thus allow for taste recognition. Furthermore, saliva 
contains salivary amylase which aids in the breakdown of food for proper 
digestion. It also acts as the buffering agent against acidic insult from food or 
regurgitated acid to protect the oral and oropharyngeal mucosa.13  
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Salivary Gland Hypofunction versus Xerostomia 
Lack of saliva can lead to morbid effects on the dentition and the soft 
tissue of the oral cavity.  In order to make a clinical diagnosis, it is important that 
one is able to distinguish the symptomatic feeling of mouth dryness, or 
xerostomia, and the clinical measurement of decreased salivary flow or salivary 
gland hypofunction. The feeling of oral dryness due to a possible decrease in 
saliva or complete lack of saliva is known as xerostomia.14   
Xerostomia, or “dry mouth” is the subjective sensation of mouth dryness 
that is often but not always associated with salivary gland hypofunction.15 It 
affects 1 out of every 4 or 5 people, and 40-60% of the population between 60-
80 years of age complains of dry mouth. Causes of xerostomia include 
dehydration, aging, smoking, mouth breathing, certain medications and various 
physiological or psychogenic conditions. To date, over 500 medications have 
been associated with mouth dryness.15, 16  
Salivary gland hypofunction refers to the decrease in measurable saliva 
production or flow rate and can be the cause of the subjective dryness otherwise 
known as xerostomia. Quantitatively, salivary hypofunction is defined as 
secretion volumes at or below 0.100 mL/min.17 Normal median salivary flow 
rates are between 0.300-0.400 mL/min when measuring unstimulated saliva.14 
There are several ways that salivary hypofunction can be assessed depending 
on the variable that is being measured.  
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 Diagnostic tests to determine and evaluate salivary hypofunction include 
measuring the rate of unstimulated whole salivary output by means of the 
draining or drooling method, in which a patient’s head is tilted forward and saliva 
is drooled into a sterile container. An unstimulated whole saliva flow rate of less 
than 0.1 mL/min is suggestive of salivary gland hypofunction. Stimulated whole 
saliva is collected by challenging the salivary glands through mastication, such 
as chewing paraffin wax, or through gustatory stimulation by means of citric acid, 
followed by expectoration into a collection tube. Stimulated whole saliva flow 
rates below <0.7 mL/minute suggest salivary hypofunction.15 
Often, patients’ response to a health questionnaire in conjunction with a 
clinical evaluation are used to evaluate xerostomic and low normal salivary 
output or hypofunction. The subjective findings from questionnaires will elucidate 
those patients that the sensation of have xerostomia while the clinical 
quantifiable measurement of salivary output determines salivary hypofunction. 18 
In this study, the quantifiable variable of salivary output was assessed as part of 
the inclusion criteria.  
Diagnosis of Xerostomia         
A thorough medical and dental history should be taken to properly confirm 
xerostomia. Questions to ask the patient include: 
• Does the amount of saliva in your mouth seem to be too little? 
• Does your mouth feel dry when eating a meal? 
• Do you sip liquids to aid in swallowing dry food? 
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• Do you have difficulty swallowing? 19 
Upon confirmation of these symptoms, further questioning of medical history 
details is integral. Several systemic and medical causes are linked to oral 
dryness. Temporary hypofunction can be caused by short term drug use (e.g. 
antihistamines), viral infection (e.g. mumps), dehydration, or psychological 
dysfunction (e.g. anxiety).20 
Chronic hypofunction can be caused by the multiple factors shown in Table 1: 
  
 
Table 1 Chronic Causes of Dry Mouth20 
Chronically administered drugs  
Autoimmune disorders Sjögren Syndrome 
 Primary Billiary Cirrhosis 
Endocrine Disorders Diabetes Mellitus 
 Hypothyroidism 
Infections Human Immunodeficiency Virus 
 Hepatitis C  
Neurological Disorders Parkinson’s Disorder 
 Bell’s Palsy 
Genetic Diseases Cystic Fibrosis 
 Down Syndrome 
 Celiac Disease 
Nutritional Deficiencies  
Head and neck radiation  
Graft versus Host Disease  
Bone Marrow Transplant   
 
 
Several systemic diseases can lead to xerostomia or salivary 
hypofunction due to the mechanism of the disease process. Mechanisms include 
infiltration of the immunocompetent cells or granuloma formation which can be 
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seen in human immunodeficiency virus, graft versus host disease, sarcoidosis, 
and tuberculosis. Polyuria and dehydration with concomitant dry mouth can be 
seen in diabetes mellitus and end-stage renal disease. Fibrosis results in 
xerostomia in conditions such as graft versus host disease and scleroderma. 
Protein deposition and bacterial infection can also be causes for xerostomia. 
Identification of the cause can lead to proper diagnosis and treatment.21  
Furthermore, a head and neck examination should be completed to 
assess whether or not salivary glands are producing adequate amounts of 
saliva. The healthcare provider should palpate the glands to assess for any 
enlargement, tenderness, or masses. 15 
Medication Induced Xerostomia      
 The use of systemic medications is one of the most frequently reported 
causes of dry mouth. Such would be expected given the large proportion of the 
population that is on prescription medications. It is estimated that up to 80% of 
the population over 60 takes prescribed medications, and 20-30% of all 
combined age groups do the same. It has been reported that hundreds of drugs 
can lead to the feeling of xerostomia including analgesics, anorectics, 
antianxiolytics, antiarrhythmics, anticholinergics, anticonvulsants, 
antidepressants, antidiarrheals, anti-emetics, antihistamines/decongestants, 
antihypertensives, antiparkinsonians, antipsychotics, antispasmodics, and 
diuretics.22   
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Given the broad range of use of these medications, the severity of dry 
mouth is variable. Furthermore, it is uncertain how much salivary gland 
hypofunction and decrease in salivary flow can be attributed to medication 
induced xerostomia as very few objective studies on the effect of medication on 
salivary output have been completed. 23  
Medications tend not to damage the salivary glands but they may 
decrease salivary flow rate by targeting certain steps in the salivary reflex both 
peripherally and centrally. Medications used for irritable bladder or chronic 
obstructive pulmonary disease block peripheral cholinergic muscarinic receptors 
on salivary gland acinar cells. Tricyclic antidepressants have targets in both the 
peripheral and central nervous systems. Adrenergic agonists are known to 
cause medication-induced xerostomia; however, there is no evidence to show 
that these medications lead to a decrease in salivary secretion. Beta-blockers 
are reported to decrease the protein concentration in saliva thus leading to a 
xerostomic state. Alpha-2 receptor agonists such as clonidine can cause both 
medication-induced xerostomia and medication-induced salivary hypofunction. 
Mixed serotonin and noradrenaline reuptake inhibitors may similarly activate 
alpha-2 receptors with the centrally occurring accumulation of noradrenaline, 
and thus are also known to lead to medication-induced xerostomia and 
medication-induced salivary hypofunction. Acting in a similar mechanism, 
opioids also produce a drying effect in the oral cavity. 23 Medications known to 
cause xerostomia are listed in Table 2.  
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Table 2 Medications Known to Cause Xerostomia14, 24 
Antidepressants  Amitriptyline, Bupropion hydrochloride, Citalopram, 
Clomipramine, Desipramine, Doxepin, Duloxetine, 
Escitalopram, Fluoxetine, Fluvoxamine, 
Imipramine, Mirtazapine, Nortriptyline, Paroxetine, 
Protriptyline, Reboxetine, Sertraline, Trazodone, 
Trimipramine, Venlafaxine 
Antihistaminic agents  Carbinoxamine, Cetirizine, Clemastine, 
Desloratadine, Dexchlorpheniramine, 
Dimenhydranate, Diphenhydramine, Fexofenadine, 
Hydroxyzine, Levocetirizine, Loratadine, Meclizine, 
Promethazine 
Antiparkinsonian 
agents 
Amantadine, Benztropine Bromocriptine, Carbidopa 
Entcapone, Levodopa, Pramipexole, Rasagiline, 
Ropinirole, Selegiline, Trihexyphenidyl 
Neuroleptics  Butyrophenone Derivatives of phenothiazine, 
Thioxanthene 
Bronchodilators  Β2-adrenomimetics, Inhalatory cholinolytics 
(ipratropium), Inhalatory glucocorticoids 
Cholinolytic agents  Atropine, homatropine, scopolamine 
Hypotensive agents  Angiotensin-converting enzyme (ACE) inhibitors: 
Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, 
Moexipril, Perindopril, Quinapril, Ramipril, 
Trandolapril 
Alpha-agonists: Clonidine, Guanabenz, 
Guanfacine, Methldopa 
Beta- blockers: Acebutolol, Atenolol, Bebivolol, 
Betaxolol, Bisoprolol, Carvedilol, Esmolol, Labetalol, 
Metoprolol, Nadolol, Penbutolol, Pindolol, 
Propranolol, Stalol, Timolol 
Diuretics: Bumetanide, Furosemide, Torsemide 
Calcium channel blockers: Amlodipine, Diltiazem, 
Felodipine, Isradipine, Nifedipine, Nimodipine, 
Verapamil 
Opioids  Codeine, Methadone, Morphine, Pethidine 
Immunostimulants  Interferon-alpha 
Appetite suppressants  Siberian 
Antimigraine drugs  Rizatriptan 202 M 
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Additional effects on oral tissues can also be seen. In a study by Leal, dry or 
cracked lips were more readily seen in patients taking medications with 
xerostomic potential.25 The oral mucosa may lose its glistening appearance 
which is indicative of dried mucous membranes. The oral mucosa may also 
appear thin and pale, while fissuring and lobulation of the tongue may be seen. 
These patients can also be more susceptible to fungal overgrowth thus 
producing angular cheilosis/cheilitis. Evidence of candidiasis can also be seen 
on the palate and tongue. Dry mouth makes patients more susceptible to 
denture stomatitis, and the lack of the saliva barrier may also increase 
susceptibility to dental caries. Saliva tends to appear thicker and stringy as 
opposed to less viscous and lubricating as seen in non-medicated patients. The 
salivary glands are often difficult to stimulate to produce more saliva due to lack 
of water, damage to the glands, or interference in the neuronal control of the 
glands. Swelling of the salivary glands can also be noted.17 Multidrug therapy 
can result in a synergistic decrease in salivary flow and thus make the 
symptoms of dry mouth even worse.16 For the purpose of this study, chronic 
medication use (greater than one year) from the aforementioned categories was 
considered in the inclusion criteria. In an effort to limit our patient population to 
medication induced xerostomia, we also excluded patients with certain systemic 
diseases that are strongly associated with reduced salivary output from the 
study. 
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Current Management of Xerostomia  
Treatment planning to alleviate dry-mouth symptoms should be tailored to 
the individual patient. A multidisciplinary model of care for xerostomia and 
salivary gland hypofunction should include the following components: 
• Patient education—a patient-centered process emphasizing daily oral 
hygiene, regular dental visits, use of topical fluoride, tobacco-use 
cessation counseling, and other interventions. 
• Management of systemic conditions and medication use in consultation 
with the patient’s physician, oncologist, or other health care providers.  
• Preventive measures to reduce oral disease and associated 
complications. 
• Pharmacological treatment with salivary stimulants (sialagogues). 
• For patients who cannot tolerate sialagogues, palliative measures to 
improve salivary output, such as use of sugar-free salivary stimulants (for 
example, chewing gum).15  
It is important to manage both the subjective and objective symptoms with 
which these patients present, whether the patients have salivary hypofunction or 
medication-induced xerostomia. Pharmacological treatment of medication-
induced xerostomia includes administration of xylitol, salivary substitutes, and 
peripherally or centrally acting sialagogues. 
Xylitol causes the osmosis of water from the tissues to the oral cavity thereby 
coating the teeth and increasing the salivary pH. Xylitol thus may have an 
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anticariogenic effect. Currently, the most effective salivary substitutes providing 
lubrication are glycerin and carboxymethyl cellulose based products.  The 
viscosity of these agents plays a major role in the subjective palliative relief 
achieved by patients. Those agents that are most similar to normal saliva appear 
to provide more relief.  
Peripheral sialagogues include ascorbic and malic acid. These agents 
produce an enhanced gustatory response; however, due to their acidic nature, 
further demineralization of teeth can occur.  
Centrally acting sialagogues include pilocarpine and cevimeline. Pilocarpine 
is a nonselective muscarinic agonist and can thus produce side effects of 
sweating and gastrointestinal upset. Cevimeline has a higher affinity for the M3R 
receptor, which is associated with salivary gland secretions. These two 
medications are contraindicated in patients with uncontrolled asthma and narrow 
angle glaucoma. 24, 26 
Free Radicals 
Free radicals are molecules in which there is one unpaired electron thus 
making these compounds unstable. Free radicals can be positively or negatively 
charged or even neutral. There are three chemical mechanisms by which these 
species are made in nature. First, there can be a breakage in a covalent bond 
leaving each end-product with an unpaired electron. Secondly, there can be a 
loss of a single electron from a neutral molecule. Third, an additional electron 
could be added to the molecule. Creation of free radicals is a normal biological 
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process and is known as “electron transfer.” The direction of transfer of electrons 
between molecules depends on the redox potential, which is a measure of the 
affinity of a substance for electrons, in relation to hydrogen. Molecules more 
strongly electronegative than hydrogen have positive redox potentials and are 
termed oxidants. Substances less electronegative than hydrogen have negative 
redox potentials and are termed reducing agents or antioxidants. Oxidation and 
reduction reactions always work in pairs and together are termed redox 
reactions.27 
An example to consider is molecular oxygen. O2 is in a triple ground state 
in which all electrons are paired. Once another electron is added through a 
reduction process, superoxide is formed (O2•-). This molecule is a free radical as 
noted with the extra electron. Further reduction of superoxide forms hydrogen 
peroxide (H2O2). This is an example of a reactive oxygen species. Hydrogen 
peroxide can readily breakdown into the hydroxyl radical, which is one of the 
most reactive and harmful free radicals.28  
Free radicals can also be formed from sources including ultraviolet 
radiation, trauma, heat, exhaust fumes, ozone, smoking, ultrasound, and various 
other sources. Endogenous sources of free radicals include leakage from 
mitochondrial transport pathways forming superoxide and functional generation 
from immune cells including phagocytes, osteoclasts, and fibroblasts. These 
endogenous sources seem to be one of the causes for certain chronic diseases 
and aging.27  
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Reactive Oxygen Species 
Reactive oxygen species are important for homeostasis and cell signaling 
pathways. They are a product of normal metabolic processes and are important 
for normal physiology. They exist as reactive oxygen radicals or nonreactive 
radicals. For example, ·O2- is needed to end the effect of nitric oxide, which is a 
major compound involved in vascular functions, including regulation of smooth 
muscle tone and blood pressure, activation of platelets, and vascular signaling.  
Cells have several endogenous antioxidants that keep the reactive 
oxygen species at controlled levels. These compounds include vitamin E, 
ascorbic acid, and glutathione. In addition, several enzymes such as catalase 
and superoxide dismutase are involved in reactions with or the breakdown of 
these reactive species, most often resulting in water as the byproduct. As a 
consequence of these mechanisms, the levels of reactive oxygen species are 
fairly low. However, damage can occur when levels of reactive oxygen species 
increase.29  
The Problem with Oxidative Stress in Oral Health 
An important aspect of this research is the correlation between 
inflammation and oxidative markers in saliva. Studies have concluded that part 
of the problem with low levels of saliva is the resulting low levels of 
antioxidants.30  Inflammation and oxidative stress start with a proliferation of free 
radicals including reactive oxygen species. Free radicals are molecules that 
have an unpaired electron and attempt to “steal” electrons from other molecules. 
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Unchecked, the process of “electron theft” can result in deterioration of cell walls 
and ultimately cell or tissue damage. In the oral cavity, free radicals can result 
from external sources, such as alcohol, nicotine, and hydrogen peroxide, as well 
as dental procedures and materials, including veneers, implants, and crowns. 
Infection due to gingivitis, periodontitis, or even root caries also generates free 
radicals as part of the inflammatory response.30 
An overabundance of reactive oxygen species or free radicals results in 
oxidative stress. Prolonged oxidative stress can lead to a chronic inflammatory 
state including systemic inflammatory disease.31 However, oxidative stress is 
reversed as free radicals are neutralized through the work of antioxidants. These 
large, complex molecules are able to “donate” electrons to free radicals in order 
to halt their electron theft. As a portal of entry to the body, the oral cavity is 
subjected to oxidants at all times which could potentially alter the redox potential 
and cause damage to oral tissues. Saliva contains several low molecular weight 
antioxidants to combat these harmful effects of the oxidants. Furthermore, 
additional sources of antioxidants include red blood cells extravasated from 
capillary beds. Red blood cells act as sinks for reactive oxygen species. 
However, hemorrhage can lead to iron catalyzed hydroxyl formation. Thus, red 
blood cells must remain in a balanced state.32  Furthermore, the interaction of 
polyphenol coated red blood cells with low molecular weight antioxidants seems 
to have a synergistic effect in combating insult to the oral cavity.32-34  
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Normal saliva is rich in antioxidants, including uric acid, albumin, ascorbic 
acid, glutathione, and antioxidant enzymes.  When antioxidant levels in saliva 
are too low to neutralize the free radicals, the tissues are set up for oxidative 
stress. In fact, several studies have implicated high levels of oxidative stress 
markers such as 8-hydroxydeoxy guanosine in oral diseases including 
periodontal disease, aphthous ulcers, dental caries, and oral cancer.35-40 Figure 
1 below describes the sources of antioxidants, the source of oxidants, the effects 
of reactive oxygen species, and ultimately the damage that can be induced. 
Furthermore, the review by Buczko proposes looking at the ratio between 
oxidants and antioxidants to accurately compare the oxidative stress levels.41 
 
 
Figure 1 Sources of Oxidants and Anitoxidants41 
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Research Supporting the Positive Effects of Antioxidants in the Oral Cavity 
Research over the past few years indicates that antioxidants are an 
important factor in dealing with free radicals and oxidative stress in the oral 
cavity. Reactive oxygen species have been known to be present in radiation 
induced salivary hypofunction patients. Studies in the mouse mode have shown 
that the administration of the antioxidant lecithinized sodiumoxide dismutase 
inhibits the deleterious dry mouth effects of radiation.42 Other studies have 
shown that prophylactic administration of antioxidants and sialagogues before 
radiation therapy may prove useful in decreasing harmful effects to salivary 
glands.43  
The antioxidant gel used in this study contains antioxidants that are 
flavonoids, specifically phloretin and ferulic acid. Flavonoids function through 
many different mechanisms such as radical scavenging, terminating lipid 
peroxidation, iron chelation, sparing vitamin E, and restoration of vitamin C. 
Published literature supports the topical use of these polyphenols in the mouth 
to amplify the total antioxidant capacity of saliva and reduce oxidative stress. 
Polyphenols are naturally found in substances such as nuts, teas, herbs, and 
vegetables. These compounds have been shown to reduce the incidence of 
carcinogenesis in the oral cavity, decrease bacterial plaque formation and 
bacterial adhesion, and inhibit viral replication. The mechanisms by which they 
act include: direct inactivation of viruses and bacteria, induction of apoptosis of 
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tumor cells, inhibition of enzymatic replication, cytokine activation via monocytes 
and macrophages, and iodination of neutrophils.44   
In particular, polyphenols have a chemical structure that allows for 
attachment to keratinocytes producing a “time release” effect in the mouth 
working in concert with salivary antioxidants to reduce oxidative stress in the oral 
cavity.33 Already, the polyphenolic antioxidants phloretin and ferulic acid have 
been shown to mitigate the adverse effects on oral fibroblasts caused by 
reactive oxygen species from nicotine, alcohol, and hydrogen peroxide. These 
compounds are the active ingredients found in the antioxidant gel that is 
examined in this study, which has been used for treatment of various oral 
conditions including oral lichen planus, gingival and periodontal disease.45, 46 
Phloretin 
Phloretin is found in the sap of apples, pears, and other fruits and 
vegetables. It has been studied for its value in skin-based drug delivery, 
attenuation of prostaglandins and therefore inflammation, and protection of the 
skin from UV radiation. Its chemical structure allows for the attenuation of 
reactive oxygen species (Figure 2), but has been most commonly used to inhibit 
lipid peroxidation. Specifically, the carbonyl side group is able to attenuate the 
effect of the radical oxygen species as hydrogen species can be spread over the 
three oxygen groups. 47 
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Figure 2 Phloretin 
 
 
In a study by Yang et al, the effect of phloretin on reactive oxygen species was 
studied in a rat model. This study was able to show successful attenuation of 
peroxidase compounds by phloretin.48 This compound has also shown anti-
inflammatory effects in lymphoid and myeloid cells.49 In the presence of 
phloretin, T cell proliferation can be inhibited by blocking CD69 and CD25 
expression.50 Furthermore, Devi and Das studied the effect of several plant 
polyphenols on normal and leukemic lymphocyte cells. Their results showed that 
phloretin was the second most potent polyphenol of those studied in inhibiting 
growth of the lymphocytic cells and the leukemic cells. Thus, the authors 
suggest that further evaluation of phloretin is warranted.51  
Ferulic Acid 
Ferulic acid is derived from leaves and seeds and is formed from the 
metabolism of tyrosine and phenylalanine. It is commonly found in foods such as 
tomatoes, corn, and rice bran.52 Due to its phenol base and extended 
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conjugated side structure, it forms a phenoxy radical that can bond to reactive 
species and inactivate them (Figure 3). Ferulic acid has been used in lotions as 
photoprotection from UV radiation. Furthermore, ferulic acid is often used as a 
food additive as it prevents the peroxidation of lipids. After binding to free 
radicals, ferulic acid forms a quinone methide intermediate product which is 
excreted through the bile.46, 52, 53 
         
Figure 3 Ferulic Acid 
 
 
 
 Ferulic acid’s prolonged bioavailability allows it to have a long lasting 
effect. It has been shown to remain in the blood longer than antioxidants like 
Vitamin C. Ferulic acid has also been shown to control inflammation by blocking 
COX-2 induction. In addition, ferulic acid has demonstrated antidiabetic, 
anticancer, hepatoprotective, neuroprotective, radioprotective, pulmonary 
protective, hypotensive, anti-atherogenic, and antiapoptotic properties.52  
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Combination of Antioxidants 
 Carefully controlled mixtures of bioactive antioxidants have promoted the 
proliferation and migration of human oral fibroblasts.46 A 2009 review reported 
epidemiologic, animal, and in vitro studies with good evidence that directly and 
indirectly support the potential preventive effect of polyphenols against oral 
cancer. Consistent studies showing that polyphenols inactivate periodontal 
pathogens and increase antioxidant capacity of oral fluids further suggest a 
preventive effect against periodontal disease.54 
Xerostomia and Oxidative Stress   
Saliva has been shown to be the first line of defense against reactive 
oxygen species. In a decreased saliva state, such as in medication-induced 
salivary gland hypofunction, reactive oxygen species such as peroxidases can 
flourish. Oxygen radicals mediate apoptosis thus causing oxidative damage to 
membrane lipids and proteins, and reducing their function. The lack of 
antioxidants has been implicated in tissue damage leading ultimately to oral 
dryness.55, 56 Oxidative stress is also implicated in some forms of salivary gland 
hypofunction. Ryo, et al report that 8-hydroxydeoxyguanosine levels are 
markedly increased in Sjögren’s syndrome patients, but such is not found in 
patients suffering solely from dry mouth.56 A similar finding was found in a study 
by Norheim et al, in which patients with Sjögren’s syndrome showed higher 
levels of certain oxidative stress markers including both protein carbonyl and 
advanced oxidation protein products. 57 A general nonsignificant trend showing 
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decreased values of oxidative stress have been seen over time with the use of 
antioxidant products in addition to increased levels of salivary flow.56 
Oxidative Stress Marker 8-hydroxydeoxyguanosine 
There is extensive experimental evidence that oxidative damage 
permanently occurs in lipids of cellular membranes, proteins, and DNA. In 
nuclear and mitochondrial DNA, 8-hydroxy-2′-deoxyguanosine (8-OHdG) or 8-
oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) is one of the predominant forms 
of free radical-induced oxidative lesions, and has therefore been widely used as 
a biomarker for oxidative stress.58 Kasai and Nishimura first reported the 
formation of 8-hydroxy-2-deoxyguanosine by oxygen radicals in 1984. The goal 
is to trap the reactive mutagens as guanine derivatives when many mutagens 
react with nucleic acid bases, and particularly guanine. 8-
hydroxydeoxyguanosine is a product of oxidative DNA damage following specific 
enzymatic cleavage after 8-hydroxylation of the guanine base. Singlet oxygen, 
photodynamic action, or hydroxyl radicals are responsible for the formation of 8-
OHdG. The oxidized DNA is continuously modified, and the excised DNAs are 
excreted in the serum and urine. Thus, the levels of oxidative stress can be 
measured with this byproduct in serum, urine, and saliva. 59-61  
The 8-hydroxy-deoxy guanosine marker has been used as a marker for 
oxidative stress in several conditions such as diabetes mellitus, cancer, 
depression, and periodontal disease. 62, 63,60  With diabetes mellitus, the 
overproduction of reactive oxygen species from the mitochondria leads to an 
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increase in advanced glycosylated end-products and therefore increased end 
organ complications. In mouse models, the reduction of reactive oxygen species 
appears to mitigate impaired angiogenesis and wound healing effects.64  
The onset of cancer and its progression has also been linked to damage 
in DNA from reactive oxygen species via DNA mutations, genome instability, 
and cell proliferation.65 A similar mechanism of damage is noted in depressive 
disorders. Direct damage to neuronal cells of the hippocampus and frontal 
cortex may explain some of the degeneration associated with psychological 
disorders.66  
Furthermore, in the presence of chronic inflammation, such as in 
periodontal disease, reactive oxygen species can accentuate damage in the 
tissues. A study conducted by Sezer et al examined at the differences between 
healthy patients with a normal periodontium and those with chronic periodontitis. 
In this study, normal salivary 8-OHdG levels were reported to be 1.56 +/- 0.12 
ng/mL.67 However, there are other studies that have reported that oxidative 
stress levels measured with 8-OHdG do not change in saliva.35 Other studies 
report that patients with dry mouth as a result of systemic disease such as 
Sjögren’s syndrome will produce an increase in oxidative stress. However, the 
healthy counterparts do not show any change in 8-OhdG levels. 68     
Based on an extensive review of the literature, there is strong evidence 
that free oxygen radicals play a detrimental role in the development of salivary 
gland hypofunction. There is also evidence that diminished levels of saliva are 
23 
associated with subtle or obvious inflammation of the oral soft tissues, which is 
also adversely influenced by free oxygen radicals. Evidence appears to indicate 
an attenuation of reactive oxygen species and increase in cell viability with 
treatment of antioxidants.69 It is not known whether the perceived presence of 
dry mouth in patients taking medications reported to be associated with 
xerostomia represents a true reduction in salivary output. Therefore, it was the 
purpose of this study to evaluate the role of locally applied antioxidant gel 
therapy in management of medication-induced xerostomia.  This study 
examined changes in salivary flow rate and ROS levels in patients with 
medication-associated xerostomia before and after use of antioxidant gel. 
CHAPTER II 
MATERIALS AND METHODS 
Overall Strategy 
This prospective study was a nested, crossover, randomized, clinical trial 
testing the effect of a topically applied active antioxidant gel against a placebo in 
improving the quality and quantity of saliva in patients with medication related 
dry mouth.  Changes in the function (using salivary analysis of oxidative stress 
marker 8-hydroxy-deoxyguanosine) and flow rates of saliva were determined at 
baseline, two weeks and four weeks prior to crossover and again at baseline, 
two and four weeks after crossover (Figure 4). 
Methodology 
In this study, 43 human patients with a complaint of dry mouth and 
medication-associated xerostomia were screened. For the purpose of this study, 
a patient with “medication-associated xerostomia” was defined as a subject who 
has been using at least one systemic medication for at least a year that has 
been reported to cause xerostomia as a side effect, and who does not have a 
history of Sjögren’s syndrome, sarcoidosis, head and neck radiation therapy, 
and other uncontrolled systemic diseases. Upon enrollment, each subject 
provided a salivary sample. Each participant was given a gel to use at home, 
blinded to which is the active gel or inactive placebo. At the initial visit, informed 
consent was obtained, saliva collected, and instructions given to use a pea sized 
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amount of the gel three (3) times per day: after their normal oral care regimen in 
the morning, mid-day after eating, and just before bed. Patients were instructed 
to apply the gel directly with their finger to the intraoral tissues. Patients returned 
to Texas A&M University College of Dentistry (TAMUCOD) at 2 weeks and 4 
weeks after the initial meeting for saliva sampling. Upon completion of 4 weeks 
of using the active gel or placebo, all patients stopped using any gel product and 
continued only with their normal oral care regime for a period of 2 weeks 
(washout period). At the conclusion of the two-week washout period, patients 
were required to visit TAMUCOD to provide salivary samples to establish a new 
baseline at week 6. At that visit, they were given the second gel and instructed 
to resume the same usage schedule of three (3) times per day. Participants 
were asked to return to TAMUCOD at 8 weeks and again at 10 weeks to provide 
saliva samples (Figure 4).  
 
Figure 4 Study Schedule 
 
 
The gel products were arranged in numerical order from 1 to 43 marked 
as either A or B. Therefore, the gels were marked as 1A, 1B, 2A, 2B, 3A, 3B and 
so on. The A, B code was randomized with respect to the active gel versus 
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placebo such that neither the patient nor investigator knew if a given patient’s A 
or B is the active or placebo gel. Furthermore, it was unknown how many 
patients had the active gel or placebo during the pre- or post-crossover period. 
Patients were assigned the number on their product series; e.g., John Smith has 
product 2A and 2B, so John Smith was referred to as “2” throughout the study to 
ensure privacy.  Patients did not undergo dentist/hygienist dental prophylaxis, 
debridement, or scaling and root planing during the trial period and were 
instructed to use their standard oral care regime. Patients were also instructed to 
continue all medications including those that may cause xerostomia.  Patients 
received the following for participating in the study: $15 per visit to cover travel 
expenses and time from work.  
a.    Patient Population 
45 patients were screened for the study. At the initial visit, patients 
consented to participate in the study and provided a salivary sample for baseline 
salivary flow rate calculation. Past medical and dental records were reviewed to 
determine probable cause of xerostomia. Patients with xerostomia likely due to 
medication were admitted into the study as indicated by their current use of 
medications known to have dry mouth as a side effect. The saliva sample was 
used for further evaluation of the oxidative stress marker- 8-
hydroxydeoxyguanosine. The selection criteria included: 
Inclusion criteria: 
•     Age: 18-85 
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•     Both men and women of all ethnicities  
•     Systemic conditions: generally healthy, ASA I or II 
•     A patient who has been using at least one systemic medication that has 
been reported to cause dry mouth as a side effect for at least one year 
Exclusion criteria: 
•     Smokers 
•     Pregnant women 
•     Patients with history of head and neck radiation treatment or recent 
chemotherapy 
•     History of salivary impairments such as salivary stones or previous salivary 
gland surgeries due to neoplasm or sialolithiasis 
• History of:  
o Primary billiary cirrhosis 
o Sarcoidosis 
o Diabetes 
o HIV 
o Sjögren’s syndrome 
• Patients with an allergy to any of the following ingredients: phloretin, ferulic 
acid, thyme, sage oil, clove flower oil, xylitol 
b.          The Active Gel 
The active gel, branded by PerioSciences as AO ProVantage, contains 
compounds generally recommended as safe by the FDA, and is currently sold in 
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dental offices along with an antioxidant-containing toothpaste and mouthwash. 
The base gel includes water, xylitol, propylene glycol, PEG 12, sorbitol, 
poloxamer 407, cellulose gum, potassium sorbate, menthol, thymol, spllanthes 
acmella extract, sodium hyaluronate, caprylic/capric triglyceride, sodium 
chloride, sodium citrate, disodium EDTA. The active gel additionally contains the 
antioxidants phloretin and ferulic acid.  
The gel was launched as a cosmetic in 2010 after completion of a six-
week safety study with 100 patients. While the gel is extremely well tolerated 
and many practitioners use the gel with xerostomia conditions, no medical 
claims have been made in marketing the AO ProVantage. Anecdotal evidence 
provided by dentists indicates that AO ProVantage provides symptomatic relief 
from dry mouth that is superior to other remedies on the market.   
c.         Study Organization 
PerioSciences provided Texas A&M University College of Dentistry the 
active gel and placebo gel in identical containers. The Thesis Committee 
conducted regular meetings to monitor progress, solve problems, ensure proper 
recruitment and retention of patients, ensure proper treatment protocol, address 
potential adverse events, and review data management. 
d.         Patient recruitment plan 
Patients who participated in the study were registered patients of 
TAMUCOD.  Patients who consented to participate in the study physically visited 
TAMUCOD for evaluation, saliva collection and xerostomia assessment. 
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Informed consent was obtained from participating patients before admission to 
the trial. The informed consent document was approved by the TAMUCOD 
Institutional Review Board (IRB). A fully executed copy of the consent document 
was provided to the participant and the original maintained by the principal 
investigator. 
e.        Saliva Collection 
Patients were asked to supply a saliva sample during each visit including 
the initial visit. Patients were asked to provide this sample before eating, 
drinking, brushing, or rinsing with anything after waking up. The sample was 
collected without stimulation which took place at the beginning of the visit by 
having the patient spit into a sterile container until 5 mL of saliva was obtained or 
30 minutes of spitting was achieved. Saliva was stored frozen at TAMUCOD, 
measured to determine salivary flow rate, and tested for 8-hydroxy-
deoxyguanosine levels. 
f.         Measurement of 8-OHdG 
 Each assay kit included a 96 well plate in which two blanks, two total 
activity, two nonspecific binding, two maximum binding, two sets of standards, 
and 24 double saliva samples.  Fifty µL of DNA/RNA Oxidative Damage AChE 
tracer and Monoclonal Antibody were added to the saliva samples. The plate 
was incubated for 18 hours. The plate was then developed with Ellman’s 
Reagent and then read at a wavelength between 405 and 420 nm. The data for 
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the standard curve was plotted and compared to the sample results to determine 
8-OHdG levels between visits.  
g.       Gel Usage 
The gel tubes were weighed at every visit to monitor the quantity of the 
gels throughout the study on a calibrated scale. These values were recorded to 
ensure compliance and regular usage.  
Data Collection and Analysis 
a.       Overview 
  All saliva specimens were stored frozen in a -80º Celsius freezer at 
TAMUCOD for 8-hydroxy-deoxyguanosine analysis.  The samples were 
centrifuged at 1250g for 10 min at 4 degrees Celsius prior to freezing. 
b.        Data collection 
Forms were organized for each patient visit. Each form had space for the 
following identifiers: patient number, patient initials, treatment type, and visit 
number. Treatment/measurement performed was recorded on the form. After 
completion of a visit, investigators checked each form for accuracy and 
completeness. The information from the forms was then uploaded into a 
computer, producing primary and secondary data files. The data entry procedure 
was designed to allow only codes listed on the form and values in the expected 
format to be entered. Reports were developed to list completion status, exits, 
and forms for subsequent statistical analysis. 
c.         Confidentiality issues  
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Confidentiality of patient data was an important consideration. The 
biostatistician did not receive the patient’s name or any identifier such as 
medical record number or SSN. Copies of data forms were stored in a locked file 
cabinet in the office of the Principal Investigator. 
d.         Hardware, software, security 
The software platform for the study was Microsoft ® 2000. Programs and 
data resided on a computer at TAMUCOD. The computer was located in a room 
with restricted access. In addition to passwords necessary to log into the 
computer and receive access to the database directory, security limited entry to 
the database to only specific users via password. The study database was 
backed up to a zip disk or CD periodically. The computer was protected with an 
uninterruptible power supply (ups). 
e.         Statistical and power analysis   
For this study, 43 patients were recruited, and using a within patient 
standard deviation of 12 ng/mL power of .8, and a type I error rate of 0.05, a 
difference between treatments of 36 units was considered significant. As this 
patient population was considered to be highly motivated, a 20% drop-out rate 
was assumed, therefore up to 45 patients could be recruited for this study. 
f.  Summary of descriptive statistics 
  For normally distributed, continuous data, means and standard deviations 
were used to describe the demographic and clinical characteristics of the patient 
population participating in the study.  Active gel and placebo groups were 
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compared using a paired t-test. Further analysis of subjects with salivary flow 
rates below 0.200 mL/min was completed. Analysis for subjects with salivary 
hypofunction and flow rates below 0.100 mL/min was also completed.  
g. Description of analysis for primary hypothesis 
The primary hypothesis of the study was that the active gel will decrease 
8-OHdG in saliva compared to placebo. A linear mixed model statistical analysis 
was used to examine the outcome variable 8-OHdG.  The between factor was 
the two treatment groups (active gel versus placebo gel), while the within factor 
was the time measurements made (baseline, 2 week, 4 week, 6 week, 8 week 
and 10 weeks). 
h.   Description of analysis for secondary hypotheses 
The secondary hypothesis was that active gel provides better treatment 
outcomes than placebo included: 
• Salivary flow rate increases with the use of the active gel. In this analysis 
the time measurements included baseline, week 2, week 4, week 6, week 
8 and week 10. 
i. General Statistical Issues 
• IBM SPSS V20 was used to analyze these data. 
• All tests, unless otherwise noted, were performed using p < 0.05. 
• Treatment of missing data- the following procedures were used to 
account for the effects of missing data on the analysis: 
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• No variables were included in the analyses that had more than 
10% of the values missing.  Variables with values missing 10% of 
the time or more do not occur by chance, and there are systematic 
causes for missing data at frequencies at this level.  Analysis 
strategies include performing the analysis using the following 
strategies: 
▪ Use of MIXED.  In MANOVA, ANCOVA, or ANOVA models, 
missing data have historically caused serious statistical 
analysis problems.  Missing data, when using a mixed 
models approach (as MIXED in SPSS), is not as serious a 
problem.  In a mixed models approach the patient is 
considered randomly chosen from a larger group of 
subjects.  These models have been found to be tolerant of 
missing data as long as the missing data are random. 
d)   Check of assumptions 
For all analyses performed, each statistical test was checked to verify that the 
assumptions for each were satisfied and, if not, appropriate transformations 
(e.g., log transformations for counts, arcsine square root transformations for 
proportions, etc.) were performed before analysis.  Non-parametric analyses 
were used where indicated. 
e)   Type I error rates 
34 
Multivariate analysis of variance was used, wherever feasible, rather than 
individual analysis of covariance adjusting for Type I error rates using Bonferroni 
corrections.
CHAPTER III 
RESULTS 
Of the 45 subjects screened, 43 subjects consented to participate in the 
study. Two subjects were excluded as one did not meet the inclusion criteria and 
the other denied being interested in participation into the study. Seven subjects 
were lost to drop out. Three subjects reported scheduling conflicts and were 
unable to adhere to the scheduled 2-week interval appointments. One subject 
was excluded as he began smoking cigarettes. One subject reported contracting 
influenza and was unable to adhere to the 2-week appointment schedule. One 
subject reported a flare up of lichen planus and discontinued use of the gel. One 
subject reported an allergic reaction consisting of edema and erythema of the 
lips. Subject’s symptoms subsided immediately after discontinuing use of the 
gel. Thirty-six subjects completed the study. 
After completion of the study, the investigators were informed of the code 
for the placebo and active gels. At that time, it was determined that 21 subjects 
began with the active gel and 15 subjects received the placebo gel first. This led 
to the creation of the A-P (active-placebo) and P-A (placebo-active) groups 
consisting of 21 and 15 subjects, respectively (Figure 5). The A-P group had 7 
males and 14 females with an average age of 57±19.01 years. The P-A group 
had 4 males and 11 females with an average age of 61.62±10.52 years (Figure 
6). The A-P group had an average usage of 11.2 g +/- 5.7 g usage per gel tube. 
35 
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The P-A group had an average usage of 11.7g +/- 7.3 g. Thus, each group used 
similar amounts of gel per visit (Table 3). 
Figure 5 Study Outline 
Table 3 Patient Demographics 
Parameter A-P P-A 
No. of patients 21 15 
No. of dropouts 4 3 
Average Age 57.00±19.01 61.62±10.52 
Gender 7 M, 14 F 4 M, 11 F 
No. of smokers 0 0 
No. of diabetic patients 6 5 
Hba1c 6.9% 6.7% 
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Medications Taken 
All medications taken by the subjects were recorded. The largest classes 
of medications used by these subjects were analgesics and antihypertensives as 
can be noted in Figure 7. Among the analgesics, the majority of these 
medications included narcotic analgesics. The antihypertensives mostly 
contained ACE inhibitors and calcium channel blockers.  
 
Figure 6 Medications Taken by All Subjects 
 
 
8-hydroxydeoxyguanosine 
The mean 8-OHdG values from each visit are listed in Table 4. A percent 
binding was calculated by determining the sample binding/maximum binding 
(B/B0) as per manufacturer’s guidelines for statistical and analytical purposes. At 
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baseline, the A-P group has an average value of 23.16±16.91 and the P-A group 
had an average value of 19.85±12.44. At week 2, the A-P group had an average 
value of 21.98±17.08 and the P-A group had an average value of 23.87±20.46. 
At week 4, the average for the A-P groups was 23.16±17.73 and 19.80±15.63 
for the P-A group. The time between week 4 and 6 was a washout period where 
subjects did not receive any gel treatment. Week 6 marks the beginning of the 
crossover. The average baselines for the A-P and P-A groups at week 6 are 
25.14±16.37 and 21.60±18.77, respectively. The week 8 average for group A-P 
is 21.81±18.00 and the average for group P-A is 22.60±16.07. The week 10 
averages for group A-P and P-A are 22.91±19.79 and 22.78±16.41, respectively. 
There were no statistically significant differences found between the groups’ 8-
OHdG values over time (Figures 8,9). 
 
Table 4 Average 8-OHdG Measurements 
8-OH-dG (B/B0) A-P (21) P-A (15) 
Baseline 23.16± 16.91 19.85±12.44 
2 Weeks 21.98±17.08 23.87±20.46 
4 Weeks 23.16±17.73 19.80±15.63 
6 Weeks 25.14±16.37 21.60±18.77 
8 Weeks 21.81±18.00 22.60±16.07 
10 Weeks 22.91±19.79 22.78±16.41 
 
 
 
39 
 
 
Figure 7 Average Oxidative Stress Levels Over Time 
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Figure 8 Oxidative Stress Levels 
 
 
 
 
Salivary Flow Rate 
 Subjects who used the placebo gel first experienced a decrease in saliva 
and a gradual increase in saliva after switching to the active gel. Subjects who 
used the active gel first experienced an initial increase in saliva. However, there 
was a decrease in salivary flow from week 2 to 4. In group A-P, there appears to 
be an increase in salivary flow with use of the placebo gel. Using mixed model 
analysis, no statistically significant difference was found (figure 10). 
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Figure 9 Salivary Flow Rates in All Subjects 
 
 
Analysis Related to Reduced Salivary Flow Rates 
Further analysis using mixed models was completed to study the effect of 
the gel on patients with reduced salivary flow rates less than 0.200 mL/min. 20 
subjects had salivary flow rates below 0.200 mL/min. 12 of these subjects were 
in the active-placebo group and 8 subjects were in the placebo-active group. 
Figure 11 displays the change in salivary flow from the initial baseline visit over 
the course of the study. Subjects who began using the active gel as the initial 
treatment had increased flow rates over the course of the study.  
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Patients who used the placebo had a decrease in salivary flow. After 
using the active gel, salivary levels increased but were not able to reach the 
initial baseline levels.  
Salivary flow decreased during the washout period after use of the placebo gel.  
This data suggests that the active gel may have a sustained release 
effect as salivary flow rate levels did not decrease with placebo use. Figure 11 
further demonstrates the difference between the active-placebo group and 
placebo-active group. The cumulative difference in salivary flow rates in the two 
groups was statistically significant (p<.05). 
 
43 
 
 
Figure 10 Difference in Salivary Flow Rates from Baseline 
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Figure 11 Overall Differences in Flow Rates 
 
 
Figure 12 displays the average flow rates as opposed to the difference 
from baseline as in previous graphs. Subjects who used the active gel first had a 
steep increase in salivary flow, but decreased during the washout phase. Use of 
the active gel may have had a lingering effect thus producing an increase in 
salivary flow with placebo use. Subjects who used the placebo first did not show 
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much of a change in salivary flow. However, once the subjects crossed over to 
the active gel, salivary flow rates increased.  
 
Figure 12 Mean Salivary Flow Rates Over Time 
 
 
 
Furthermore, baseline measurements were compared in this reduced 
salivary flow subset as seen in Figure 13 and Table 5. The first baseline was 
measured at week 0 and the second baseline was measured at week 6 after the 
2-week washout period. There was an increase of 0.023 mL/min in the active-
placebo group and an increase of 0.04 mL/min in the placebo-active group. 
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Therefore, subjects had 5.75 times more saliva at their second baseline visit 
versus their initial baseline visit after using the active gel first.  
 
Figure 13 Comparing Difference in Salivary Flow Baselines in A-P and P-A Subjects 
 
 
 
 
Table 5 Change in Baseline Salivary Flow Rate Values 
 
 
 
Upon evaluation of the difference in baselines, there were more subjects 
in the active-placebo group that had increased second baselines at week 6. 
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There were 10 subjects in the A-P group with increased baselines and 2 
subjects with decreased second baselines. The placebo-active group had 3 
subjects with increased baselines and 5 subjects with decreased baselines as 
depicted in Figure 14.  
 
 
 
 
 
When evaluating the salivary output for weeks 8 and 10, subjects who 
began with the active gel during the first half of study had an average decrease 
of 0.0059 mL while using the placebo gel. However, subjects who first received 
the placebo gel had an average increase of 0.0924 mL after switching to the 
active gel as seen in Figure 15.  
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 Figure 14 Comparing Baselines of Subjects in Groups A-P and P-A 
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Figure 15 Difference Between Salivary Output for Active and Placebo Gel Use 
 
 
 
When comparing total salivary output (p1 + p2) during the active gel 
phase compared to total saliva output (p1 + p2) during the placebo phase, all 8 
patients that used the placebo first had more saliva in the active phase. 
However, when the active was given first 6 of the 12 patients (50%) had less 
salivary output and 6 subjects had increased salivary output in the placebo gel 
phase as seen in Figure 16.  
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Figure 16 Salivary Flow Changes After Crossover 
 
  
 
The data was then split into data sets consisting of the two groups: active 
and placebo. A data set is defined as a base line saliva sample followed by a 
period 1 (week 2 or week 8) sample and a period 2 sample (week 4 or week 10). 
Each patient provided two data sets- one with active gel use and the other with 
placebo gel use. Figure 17 shows the number of data sets exhibiting varying 
percent changes from baseline salivary flow rates (week 0 or week 6) to the 
period 1 sample. One active gel data set had an increase of 1120% from 
baseline. There were 17 active and 13 placebo data sets that had an increase in 
salivary flow rate. There were 7 data sets in both the active and placebo groups 
that exhibited decreased salivary flow rates from baseline. The range of change 
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in salivary flow rate for the active data sets is -0.099 to 0.307 mL/min and -0.082 
to 0.104 mL/min for the placebo data sets in period 1.  
 
Figure 17 Percent Change in Salivary Flow from Baseline to Period 1 
 
 
 
Figure 18 shows the number of data sets exhibiting the varying percent 
changes from baseline to the period 2 measurement. 16 active data sets had an 
increase in salivary flow rate. 9 placebo data sets had an increase in salivary 
flow rates. 6 active data sets had a decrease in salivary flow rate from baseline 
and 11 placebo data sets had a decrease in salivary flow rate. The range of the 
salivary flow rate changes for period 2 for the active data sets is -0.027 to .369 
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mL/min. The range of salivary flow changes for the placebo data sets in period 2 
is -0.095 to 0.198 mL/min. 
 
 
Figure 18 Percent Change in Salivary Flow from Baseline to Period 2 
 
 
 
 
 
As seen in Figure 19, with long term use (period 2 over baseline), there 
were 6 active data sets and 11 placebo data sets with decreased flow rates from 
baseline to period 2. There were 7 active data sets and 5 placebo data sets with 
a salivary flow increase between 1 and 99%. Lastly, there were 9 active data 
sets and 4 placebo data sets that had salivary flow rate increases greater than 
100%.  
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Figure 19 Number of Data Sets With Varying Percent Changes from Baseline to Period 2 
 
 
 
 
Analysis of Patients with Salivary Hypofunction 
Further analysis was completed for subjects having baseline salivary flow 
rates below 0.100 mL/min, otherwise known as salivary hypofunction. 12 
subjects qualified to be in this subset. 5 of 12 were in the Placebo-Active group 
and 7 were in the Active-Placebo group. The findings mimicked those from the 
analysis of the subjects with salivary flow rates below 0.200 mL/min.   
Upon evaluating the baselines of the A-P and P-A groups, subjects had 
4.54 times (0.029/0.006) more saliva at their second baseline measurement 
compared to the first baseline measurement after using the active gel compared 
to use of placebo gel as seen in Figure 20 and Table 6.  
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Figure 20 Difference in Baselines (week 0 and week 6) 
Table 6 Change in Salivary Flow Rate Baseline Values 
A-P P-A 
Average saliva measurement at first 
baseline  0.044 0.048 ml/min 
Average saliva measurement at second 
baseline  0.073 0.054 ml/min 
Increase/decrease from 1st to 2nd baseline 0.029 0.006 ml/min 
Percent Increase / decrease 65.1% 13.2% 
Specifically, 6 of the 7 Active-Placebo subjects had an increase in 
salivary flow rates from their initial baseline while one subject had a decrease in 
salivary flow rate between baseline measurements. In the Placebo-Active group, 
two subjects had an increase between baseline measurements and three 
subjects had a decrease between baseline visits as seen in Figure 21. 
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Figure 21 No. of Subjects with Increased/Decreased Salivary Flow rates at B2 
 
 
 
When evaluating the salivary output for weeks 8 and 10, subjects that 
began with the active gel during the first half of study had an average decrease 
of 0.01 mL while using the placebo gel. However, subjects who first received the 
placebo gel had an average increase of 0.06 mL after switching to the active gel 
as seen in Figure 22. 
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Figure 22 Difference in Salivary Output from Active Gel to Placebo Gel 
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CHAPTER IV 
DISCUSSION 
The results of this study fail to support the hypothesis that oxidative stress 
levels are reduced with the use of the active antioxidant gel product. There does 
not appear to be a relationship with oxidative stress levels measured with 8-
OHdG and use of the active gel or placebo gel.  Results indicate an increase in 
salivary flow rate with the use of the active antioxidant gel. There appears to be 
a lingering effect of the active gel in subjects even after the wash out period as 
seen in the elevated second baseline values. Upon evaluation of the nested 
subgroup of participants with salivary flow rates below 0.200 mL/min, a 
statistically significant difference was found between the active-placebo and 
placebo-active groups. The active-placebo group had significantly increased 
salivary flow rates compared to the placebo-active group. 
Currently, another study examined quality of life parameters associated 
with xerostomia symptoms in the same patient pool. A visual analog scale was 
used to determine the levels of difficulty speaking, difficulty swallowing, 
decreased saliva in the mouth, dry mouth, and dry throat on a scale of 1 to 10 in 
which 1 equates with rare occurrence of these symptoms and 10 means 
constant awareness of these symptoms. Qualification of xerostomia is a 
subjective finding, and thus utilization of such surveys allows monitoring of the 
xerostomia symptoms.24 Additionally, a gel satisfaction survey was used with a 
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Likert scale to determine the patient perceived effectiveness of the gel. Patients 
were asked to rate the following parameters as very satisfied, satisfied, neutral, 
unsatisfied, and very unsatisfied: 
- Time it took to feel relief after using the dry mouth gel. 
- Confidence in breath after using the dry mouth gel. 
- Ability to eat after using the dry mouth gel. 
- The soothing effect in the mouth after using the dry mouth gel. 
- The ability to sleep through the night after using the dry mouth 
gel. 
These qualitative parameters allowed for an assessment of the xerostomia 
conditions in the subjects. The only parameter that was statistically significant 
over time was the soothing effect of the gel. Patients from both the placebo-
active and active-placebo groups reported a sooth effect of the gel over time. All 
other qualitative parameter differences were not statistically significant.  The 
current study focuses on the quantitative analysis of salivary flow and oxidative 
stress levels in this xerostomic subject pool. 
8-hydroxydeoxyguanosine 
This study was unique in that it looked at the oxidative stress levels in 
relatively healthy subjects in that none of the participants reported uncontrolled 
systemic diseases. Salivary levels of 8-OHdG have been studied in subjects with 
a history of head and neck radiation, Sjögren’s, diabetes, periodontitis, and 
several other diseases.35-40 Oxidative stress levels are elevated in the 
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aforementioned disease states. However, studies have shown that healthy 
controls do not display an increase in oxidative stress levels.67 Such was the 
case seen in our study. There was great variability in the values and trends in 
the data were not found. 8-OHdG levels were reported in the results section 
according to manufacturer’s guidelines as a percentage of sample 
binding/maximum binding. Research studies report the raw values of this assay. 
Dede reports oxidative stress levels in chronic periodontitis as 605.5 pg/ml ± 
139.1 and 550.52 pg/ml ± 150.28 in healthy patients.35 Raw data from this study 
produced baseline (week 0) values of 374.23±141.79 pg/mL for group P-A and 
407.81±155.03 pg/mL in the A-P group. Reasons for this difference could be a 
difference in the inflammatory process associated with chronic periodontitis. 
Subjects in this study did not necessarily have inflamed tissue or signs of 
erythema. The range of the 8-OHdG values within 1 standard deviation found for 
healthy individuals in Dede’s study is within the same range of oxidative stress 
values found in the A-P group in this study. The P-A group started out with a 
slightly lower oxidative stress baseline value. However, the range within one 
standard deviation for both the A-P group and P-A group overlaps so there is not 
a significant difference between these two groups. To the best of our knowledge, 
this was the first study to look at oxidative stress levels in medication induced 
xerostomic patients, thus comparative values are those from other studies 
reporting “healthy” individuals.  
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As per manufacturer’s guidelines, assay values should be reported as a 
percentage of sample binding/ maximal binding. Most values in the literature are 
reported as raw values, however inter-assay claims should not be made in this 
metric. We observed lower levels of oxidative stress in this subject pool when 
evaluating the raw values. However, other studies reporting oxidative stress 
levels in saliva do not report the percent binding of their sample thus fair 
comparisons are difficult to make.  
Furthermore, studies measuring salivary oxidative stress have reported 
that salivary oxidative stress levels do not necessarily change between healthy 
and test groups. Rather, serum levels may prove to be more reliable markers. 
This finding may also explain the lack of difference found in the groups over 
time.35 Future studies observing the serum oxidative stress levels may prove 
useful.  
The lack of a significant difference in oxidative stress could also be 
explained by the lack of significant statistical differences in the qualitative 
parameters noted in the xerostomia visual analog scale. Subjects reported a 
statistically significant difference from baseline to week 10 regarding the 
satisfaction with the soothing effect of the gel with both the placebo and active 
gels. However, there was not a statistically significant difference between both 
groups.  
After analyzing the qualitative data for subjects with reduced salivary flow 
rates (<0.200 mL/min, n=20), there does not appear to a be a correlation with 
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XVAS values and second baselines values. Subjects who had elevated second 
baseline values did not necessarily report less occurrence of xerostomia 
symptoms. This same analysis was completed for subjects with salivary flow 
rates >0.600 mL/min (n=7). No significant correlation was found between 
xerostomia visual analog scale values and salivary flow rates. Three subjects in 
this group showed an increase in salivary flow rates with use of the active gel, 
and four subjects showed a decrease in salivary output with use of the active 
gel.  
A potential weakness in this study includes the need for stricter exclusion 
criteria. The only social habit accounted for in the exclusion criteria was tobacco 
use. Subjects were not asked to halt alcohol or caffeine use. Most subjects 
reported social drinking and intake of some tea or coffee daily. Changes in levels 
of consumption of these could alter the salivary flow rates.17  Also, periodontal 
examinations were not completed for the study participants. Periodontal disease 
is known to increase oxidative stress levels.27 Furthermore, any ulcerations or 
erythematous lesions could increase oxidative stress levels.70 Thus, variability in 
the data could be explained if active disease was present in any of the 
participants. The initial chief complaint of the majority of the study subjects was 
the occurrence of dry mouth and secondary symptoms related to the dryness.  
This study was conducted from Fall 2015 to Summer 2016. Several 
subjects informed the investigators regarding seasonal allergies occurring during 
the change of seasons. Patients using antihistamines for relief from seasonal 
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allergies such as cetirizine are known to have dry mouth as a side effect. 
However, use of this medication or other similar medications was not grounds 
for exclusion in the design of this study. Such circumstances are out of the 
control of the investigators but may explain some variability in the 
measurements. 
Other oxidative stress measures could have been used to observe the 
effect of the use of the active and placebo gels. Other studies have reported use 
of malondialdehyde and 4-hydroxy-2-nonenal to assess levels of lipid 
peroxidation. Values of advanced glycosylated end products can act as another 
biomarker for oxidative stress levels. However, great variability has been seen in 
all of these markers.  
Salivary Flow Rates 
This study is a nested, double blind, placebo controlled, crossover, 
randomized clinical trial. This study design has some limitations that must be 
addressed when interpreting the results. As was the case in this study, 
crossover studies allow subjects to be exposed to both the active and placebo 
products. However, it does not allow a comparison with the gold standard of 
therapy. In this study, the subjects and investigators were blinded to the mode of 
therapy to avoid introduction of a bias that would compromise the validity of the 
study. Comparing the active gel to another product such as a sugar free gum or 
an oral sialagogue would be easily discernable as they have different vehicles of 
administration. This could potentially introduce bias into the study from either the 
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participants, investigators, or both. Furthermore, there is a lack of evidence 
recommending one treatment modality over another, thus there is not a gold 
standard for treatment of xerostomia.15, 71   
Reduced Salivary Flow Rates 
A lingering effect was apparent after the use of the active gel, specifically, 
in the participants with salivary flow rates below 0.200mL/min. The use of a 
placebo can introduce the placebo effect and thus increase the half-life of the 
active product in a cross over study design. Research shows that verbal, 
contextual, and social cues can elicit responses that cause the subject to 
remember the sensations from previous events and create an expectancy that 
for what is likely to be experienced in the current situation.72 To apply this 
behavior in the current study, one could expect that the subjects who received 
the active gel first create an expectation that gel application, regardless of its 
ingredients, will alleviate dryness. The process of gel application can actually 
stimulate a response in the central nervous system that produces physiologic 
change without the active stimulus. Furthermore, a “nocebo” effect has also 
been described in the literature in which subjects, who believe they have 
received the placebo first, assume that there are no active effects and can 
develop negative results.73 
Another behavioral modifier that could have altered the outcomes in this 
study is the Hawthorne effect, in which people tend to alter their behavior when 
they are being observed. Subjects may perform more positively due to an 
63 
 
 
increased interest in their actions. 74 This could potentially explain the increased 
second baseline salivary flow rates in the group of subjects who received the 
active gel first. However, it is difficult to know if the Hawthorne effect or even the 
placebo effect could cause physiologic changes such that salivary flow rates 
would increase over the course of the study.  
Another limitation in the study design may be the length of the study. 
Perhaps a longer wash out period was needed to return to initial baseline levels 
or greater amount of time was needed in between visits to observe the effects of 
the antioxidants. Current knowledge does not indicate the length of time 
antioxidants are retained in tissue thus further studies are needed to investigate 
this molecular interaction.  
One of the major strengths of this study is that subjects were appointed 
for salivary measurement almost 10 hours after their most recent gel 
applications. Subjects were instructed to use the gel three times a day: morning, 
after lunch, and before going to bed. Subjects reported to the clinic for their 
appointments in the morning before eating, drinking, or brushing. Thus, their last 
application would have been from the previous evening. Finding statistically 
significant differences in salivary flow rates after that long span may provide 
merit to the finding of increased salivary flow rate. 
Also, compliance was strictly enforced by measuring gel samples at each 
visit to ensure usage of gel. Subjects were thoroughly instructed on gel 
application to avoid confusion of the application protocol.  
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Furthermore, during analysis of the subject pool in this study, it was noted 
that subjects taking analgesics were most common in the reduced salivary flow 
rate group. Studies have noted that subjects taking narcotics are 2.4 times more 
likely to report xerostomia. Studies have also shown that antidepressants and 
anxiolytics are also responsible for increased reports of xerostomia.75 Greater 
communication with the physicians prescribing these medication and with the 
patients taking these medications may help in managing the side effect 
xerostomia.   
At this time, it is unknown how long antioxidants can be retained in the 
oral tissues. Future studies examining the absorbance mechanism may prove 
useful to understand the cell biology associated with antioxidants in the oral 
cavity. There is evidence to suggest the lipophilic polyphenols need blood cells, 
platelets, and salivary proteins to increase the solubility of the antioxidants in 
whole saliva.34 However, due to the lack of quantity of saliva in some of the 
xerostomic subjects, there may be less antioxidant retention over time. This may 
explain why subjects with extreme dryness may not respond as well to 
antioxidant therapy as there is insufficient solvent for the antioxidants. Further 
studies evaluating the binding mechanism of antioxidants with the quality of 
saliva may provide more insight.  
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CHAPTER V  
CONCLUSION 
 
 Within the limits of this study, subjects receiving the active antioxidant gel 
first had similar levels of salivary 8OHdG before and after treatment compared to 
the subjects who received the placebo gel first. The subjects receiving the active 
antioxidant gel first had an increase in salivary flow rate over time, however this 
was not statistically significant. Nonetheless, subjects who had low salivary 
output levels at the initial baseline especially in the active-placebo group 
experienced a significant increase in salivary output that demonstrated a 
sustained positive effect throughout the washout and placebo phases of the 
study. Despite the fact that there were limitations to this study such as large 
variability in the oxidative stress data and the potential placebo effect, there may 
be a place clinically for the use of this topical combination antioxidant gel in the 
treatment of xerostomia. Future research should further investigate the efficacy 
of longer use and perhaps a heavier dosage of antioxidants. 
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